Tracer library / [44Sc]177-AAZTA5-PSMA-617

[44Sc]177-AAZTA5-PSMA-617

Radionuclide: Sc-44 t½ 238.2 min
Modality: PET
Production route: —
Stage: Preclinical
Syntheses indexed: 1

Prostate cancer Preclinical only, no clinical indication yet

What it is

Compound class: PSMA-617 urea-based ligand with AAZTA5 chelator
Target / mechanism: PSMA (prostate-specific membrane antigen) PMID 33242189
Clinical application: Prostate cancer theranostics PMID 33242189
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	none	>99%	99.9%	AAZTA5-PSMA-617	33242189 2020 EJNMMI Radiopharm Chem For 44Sc, due to the general post processing, the radionuclide is provided in 0.25 M ammonium acetate buffer pH 4 - radiolabeled in quantitative radiochemical yields (> 99%, as determined both by radio-HPLC and radio-TLC)

Need this precursor?We can point you to suppliers for [44Sc]177-AAZTA5-PSMA-617, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 33242189. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 33242189: 'AAZTA5-PSMA-617 (AAZTA5-Chx-2-NaI-Lys-Urea-Glu) was successfully radiolabeled'. | Stage 30 (2026-09-18): Modality was 'Therapy' -- a bucket value given to every agent found by the therapy-oriented bulk search (stages 21-22), not a source statement. Corrected to PET: Sc-44 is a positron emitter used only for PET imaging. Linked articles: PMID 33242189. Stage set/updated at stage 39 from PMID 33242189: 'in vitro studies on PSMA-positive LNCaP cells were performed in direct comparison to radiolabeled DOTA-PSMA-617 analogs'.